One Atom Can Change a Drug’s Fate: Atom-Level Knobs and a Functional-Group Toolbox for Medicinal Chemistry (Methyl / Halogen Bonding / 3D Building Blocks / Late-Stage Fluorination + Product-Selection Tables)

Many people imagine drug discovery as “building with LEGO blocks”: as long as the big fragments are assembled correctly, the job is done. In reality, it is closer to a precision mixing console—a single atom or a small functional group can simultaneously alter binding affinity, selectivity, solubility, membrane permeability, metabolic stability, and even safety. Because these “small knobs” have such broad impact, medicinal chemistry has coined vivid (slightly exaggerated but memorable) phrases like “magic methyl” and “magic chloro.”

1,Why can a “tiny substitution” lead to a huge difference?

• Putting a lead compound into a protein binding pocket is a lot like a key entering a lock: a tiny change in shape or interactions can determine whether binding is “just stuck” or “just right.”
• Reminder: protein pockets are not perfectly rigid. Binding is often influenced by conformational change (induced fit / conformational selection) and desolvation of water molecules.
• At the molecular scale, the relevant differences are often 0.01–0.1 nm (0.1–1 Å) in distance/space. These can come from substitutions that look “small,” such as –CH₃, –OCH₃, F, Cl, etc.
• Crucially, such substitutions often affect more than one thing at once.

In medicinal chemistry, this is called an activity cliff: two structures that are nearly adjacent, yet show a dramatic activity difference. One of the most famous examples is the magic methyl effect (adding just one methyl group can sometimes cause an order-of-magnitude jump in potency).

2,The “four knobs” of drug molecules: you are not adding a group—you are triggering a chain reaction

Knob	Core question	Common pathways to “possible gains”	Common costs	How to verify in practice
A Pocket interactions	Can it “grab the target”?	H-bonds, hydrophobic/van der Waals, π–π, electrostatics; plus halogen bonding when exploitable (often with Cl/Br/I).	Tighter binding but “stickier” (↑ non-specific binding); or a directional interaction that backfires if geometry is wrong	Binding/activity: Kd/Ki/IC50; structure: co-crystal / modeling; controls such as solvent competition / ionic strength (“salt effects”)
B Conformation & shape	Can it “pose correctly”?	Small substituents can lock conformations, displace water, reduce unproductive conformers, and increase the population of the bioactive conformation	Locking the “wrong” conformation; or ↑ flexibility → ↑ entropic penalty; worse selectivity	NMR / computational conformers; SAR with paired comparisons; structural evidence from co-crystal / cryo-EM, etc.
C Physicochemical properties (upstream determinants of ADME: absorption/distribution/metabolism/excretion)	Can it “move through the body”?	Exposure/distribution are jointly determined by solubility, logP/logD, PSA, pKa, permeability	logD↑ → solubility↓, off-target↑; or polarity↑ → permeability↓; “it binds but cannot reach”	Solubility, logD, pKa, PAMPA/Caco-2, plasma protein binding, stability
D Metabolism & safety	Can it “last longer, safely”?	Block metabolic hot spots, shift metabolic sites, improve half-life/exposure; but may redirect to new metabolites	Reactive/toxic metabolites; CYP inhibition/induction; DDI risk	Microsomes/hepatocytes stability, metabolite ID, CYP inhibition panel, hERG/early tox screens

3,Four representative “atom-level knobs”: why are they so often the protagonists of drug design?

These four “atom-level knobs” (–CH₃, –OCH₃, halogens, 3D/Fsp³ building blocks) repeatedly show up in drug design because small structural edits can simultaneously influence binding mode, conformational distribution, physicochemical properties, and metabolic pathways. However, the outcomes are highly context-dependent (target pocket + molecular environment) and must be validated with matched-pair comparisons and data.

Quick reference table: four representative “atom-level knobs”

Knob (group/strategy)	What “key changes” it often brings	Typical benefits	Typical costs	Common strategies & cautions
3.1 Methyl –CH₃ (magic methyl)	Small volume but can markedly change hydrophobic filling, water displacement, and conformational distribution; can also affect logP/solubility and metabolic sites	In specific systems, can give large potency boosts (≥10× or even ≥100×), via filling a hydrophobic subpocket, conformational locking, or shielding a metabolic site	Statistically, “big boosts” are not common; more often: logD↑, solubility↓, non-specific binding↑	A methyl walk/scan can help, but track solubility, logD, clearance in parallel; focusing only on potency easily misleads
3.2 Methoxy –OCH₃	Combines size/hydrophobicity with one HBA (H-bond acceptor); can fine-tune electronics and ADME	Reviews have systematically surveyed 230+ (about 235 by literature counts) approved small-molecule drugs containing methoxy groups and analyzed their roles via SAR/co-crystal evidence	A common liability is O-demethylation (forming a phenol), which may change exposure/activity/safety	Treat –OCH₃ as a tunable knob, not decoration: track HBA contribution and metabolic routes; consider isosteric swaps only when warranted
3.3 Halogens (F/Cl/Br/I) & halogen bonding	Cl/Br/I can provide directional halogen bonds (σ-hole); F is usually not a typical XB donor (more often used for electronics/conformation/metabolic fine-tuning)	Some matched-pair cases report extreme potency jumps for H → Cl (up to 10⁵); note: these are rare, context-dependent activity cliffs—not a general rule	Halogenation often increases logD, reduces solubility, raises off-target risk; XB geometry is stringent—wrong placement can hurt	Use halogens as pocket probes: check whether structures/controls suggest an exploitable XB site; it’s not “the more the better”
3.4 3D building blocks & Fsp³ (e.g., oxetane)	Increases 3D character/conformational complexity; may improve solubility/properties and shift metabolism/conformational preference	“Escape from flatland” proposed correlations between Fsp³/chirality and success rate, and discussed links to solubility; oxetane substitutions can strongly affect solubility, lipophilicity, and metabolic stability (highly context-dependent)	3D is not automatically better: may sacrifice synthetic accessibility or pocket fit; recent “Return to Flatland” re-evaluations caution against over-generalization	Use 3D blocks for holistic “drug-likeness” optimization: validate net gains in solubility/exposure/clearance, not just binding strength

Notes:

3.3 Note: In most organic R–F systems, F is typically not a classic halogen-bond (XB) donor (σ-hole is weak or not obvious). Its value more often lies in fine-tuning electronic effects, pKa/polarity, conformation, and metabolic sites. Only in a few contexts (e.g., strongly electron-withdrawing environments) might directional interactions appear that differ from classical XB.

3.4 Note: “Escape from Flatland” emphasizes that higher Fsp³/3D character often correlates (statistically) with higher development success rates or improved properties—but this is correlation, not causation. “More 3D” is not automatically better; pocket fit, pKa/polarity balance, solid form/crystallinity, and metabolic pathways still matter. Later work such as “Return to Flatland” has re-assessed and cautioned about over-interpreting the heuristic.

4,Why is “late-stage fluorination” a key tool in drug R&D?

Even if you already have a promising candidate, late-stage development often runs into “late problems” such as:

• Potency is fine, but exposure is insufficient (too rapid clearance, short half-life).
• Metabolism is too fast or uncontrolled (clear soft spots; metabolic rerouting introduces new risks).
• You need PET imaging to validate distribution/targeting (especially ¹⁸F labeling).

Here, the value of late-stage functionalization / late-stage fluorination is that you avoid starting over from scratch. Instead, you perform small, controllable edits on complex scaffolds, enabling shorter iteration cycles to explore SAR and property space.

Authoritative progress summary:

• A Chemical Reviews 2025 perspective titled Selective Fluorination of Complex Molecules: Late-Stage Functionalization systematically reviews late-stage fluorination strategies for complex molecules, focusing on single-atom-level fluorination edits, and discussing nucleophilic/electrophilic fluorine sources, substrate scope (natural products, analogs, drug-like molecules), and methodological boundaries.

Why is it especially critical for PET?

• ¹⁸F is one of the most commonly used radionuclides in PET (Positron Emission Tomography). Its half-life is about 109.77 min, which strongly favors introducing ¹⁸F as close to the final step as possible to reduce time cost and radiochemical decay (loss of radioactivity). Meanwhile, ¹⁸F labeling of (hetero)aromatic rings and the “late-stage” concept are also systematically discussed in radiochemistry reviews.

• Note: Late-stage fluorination is not “fluorinate wherever you want.” Feasibility depends heavily on site selectivity, functional-group tolerance, substrate complexity, scalability, and process safety. It is best viewed as a high-value toolbox, not a universal solution.

5,Making the methodology actionable: when you see a problem, which “knob” should you turn first?

Symptom (common)	Knob most likely to help	Typical “atom/functional-group actions” (examples)	Key validation (avoid misinterpretation)
Potency is not enough—just short	Binding / conformation	Methyl scan / methyl walk (add –CH₃ site-by-site in small positions); for a halogen scan, it is often clearer to write it as a Cl site scan (use Br/I only if needed); F substitutions are more often for fine-tuning electronics/conformation/pKa/metabolism	Measure in parallel: solubility, logD, metabolic stability; use structure/modeling to explain “why stronger” (avoid mistaking solubility/aggregation artifacts for real potency gains)
Selectivity is poor; off-targets appear	Conformation / interactions	Use small substituents or cyclization to “lock the pose”; search for exploitable directional interactions (e.g., Cl/Br/I-enabled halogen bonding, but only with correct geometry and acceptor environment)	Homolog/off-target panel controls; evidence for conformational distribution and key interactions (structure/mutagenesis/thermodynamic decomposition, etc.)
Solubility is too low; formulation pressure is high	Physchem / 3D	Reduce “too flat/too hydrophobic”: reduce aromatic count, introduce heteroatoms or ionizable centers; introduce 3D blocks (oxetane is one common idea, but must be validated case-by-case); when needed, consider salt, cocrystal, or prodrug strategies	Linked evaluation of solubility–solid form–salt form; computed values are only references—measure experimentally (solubility, solid-state characterization)
Metabolism is too fast; exposure is insufficient	Metabolism / physchem	Do soft-spot mapping first, then “block”: site substitution (F/Cl for electronic + steric fine-tuning), reduce exposure of easily oxidized motifs; with a confirmed rate-limiting C–H cleavage step, consider isotope strategies (e.g., deuteration)	Metabolite ID (confirm you “blocked” vs “rerouted”); microsomes/hepatocytes stability, clearance, DDI risk screens
You have a lead scaffold but want rapid expansion of chemical space	Tools & strategies	Late-stage functionalization / late-stage fluorination (including late-stage radiofluorination with ¹⁸F), quickly build matched-pair sets to probe SAR (Structure–Activity Relationship) and property space	Structural confirmation (incl. impurities/stereochemistry); compare key properties within the same batch (solubility, clearance, permeability, binding)

6,Broaden the horizon: “special” elements can also become key drug determinants

6.1 Deuterium (D): using isotopes to slow metabolism “just a little,” for better exposure

• The core intuition of deuteration is that a C–D bond is harder to break than a C–H bond. If the rate-limiting step of a metabolic pathway involves C–H bond cleavage, introducing D may create a kinetic isotope effect, lowering clearance and improving exposure. But it is not universal: if the rate-limiting step is elsewhere, or metabolism can “take a detour,” the effect may be small or disappear.

• A frequently cited milestone is that in 2017, the FDA approved deutetrabenazine (Austedo). The review materials describe it as a deuterated form of tetrabenazine for Huntington’s disease-related chorea; multiple authoritative media sources have also called it the first approved deuterated drug.

6.2 Boron (B): unlocking new mechanisms via “unique bonding modes”

• Boron often displays electron deficiency (Lewis acidity) and can interact with biological targets in ways uncommon for typical organic C/N/O systems (e.g., reversible adduct formation with nucleophiles in active sites, mimicking tetrahedral intermediates). Therefore, boron-containing functional groups (boronic acids, benzoxaboroles, etc.) are regarded as one class of “privileged structures” in medicinal chemistry.

• Approved boron-containing drugs now form a clear lineage, such as the proteasome inhibitors bortezomib and ixazomib, the antifungal tavaborole, the topical anti-inflammatory crisaborole, and the β-lactamase inhibitor vaborbactam (used as a “potentiator/protector” component in combination with antibiotics).

7,Conclusion: the “atom-level craftsmanship” of drug design

The real value of “special elements and functional groups” is not “add it and it gets stronger,” but rather:

• They are low-cost property regulators.
• They provide fine, controllable adjustments amid the multi-objective tension of potency–ADME–safety.
• Most importantly, they enable optimization to become a reusable methodology—through matched molecular pairs plus mechanistic explanations—instead of relying on luck.

8,Product Selection Navigation Table | Quickly Locate the Four Product Tables by “Real R&D / Synthesis Needs”

Need / scenario (starting from experiments & selection)	Which table to check first	What this table mainly covers	Common operational keywords
You need NMR characterization (sample dissolution, spectrum acquisition); or you plan deuteration / isotope labeling (D₂O system, introducing –CD₃) for metabolism / mechanism / internal standards	Table 1	Special elements & molecular building blocks	Deuterated solvents (DMSO-d₆, CDCl₃), D₂O; deuterated methylation reagent (CD₃I)
You want to introduce/replace 3D, high-Fsp³ fragments (increase 3D character, change conformational rigidity and hydrophobic volume); or you want to use oxetane / oxetanone / adamantane for scaffold expansion and building-block assembly	Table 1	Special elements & molecular building blocks	3D building blocks (oxetane parent, 3-oxetanone precursor, adamantane)
You need boron building blocks to rapidly assemble aryl/heteroaryl frameworks; or you want to borylate a halogenated substrate and then do Suzuki coupling to expand a compound library	Table 1	Special elements & molecular building blocks	Phenylboronic acid (PBA), B₂pin₂ (bis(pinacolato)diboron)
You are running experiments related to boron-containing drugs / tool compounds (PDE4, proteasome, β-lactamase, etc.) and need positive controls / pharmacology tools	Table 1	Special elements & molecular building blocks	Boron-containing drugs / tool compounds (Crisaborole, Ixazomib, Vaborbactam, Tavaborole, etc.)
You need O/N/S methylation (actually installing –CH₃ or –OCH₃ on the molecule) to quickly generate a set of “methyl / methoxy” analogs for property & activity comparisons	Table 2	Methyl / methoxy related	Methylation reagents (DMC, MeI solutions, sulfonates, dimethyl sulfate, MeOTf, etc.)
You want methoxy / phenolic OH model substrates for structural controls, synthetic starting materials, or property comparisons (–OCH₃ vs –OH)	Table 2	Methyl / methoxy related	Anisole; guaiacol
You need to introduce Cl/Br/I “halogen handles” (halogenated intermediates) for downstream substitution/coupling; or you need selective halogenation	Table 3	Halogenation / chlorination & activation toolbox	Selective halogenation reagents such as NCS / NBS / NIS
You need to activate carboxylic acids/alcohols into more reactive intermediates (acid chlorides, chlorides, etc.) to rapidly build amide/ester derivative libraries	Table 3	Halogenation / chlorination & activation toolbox	Oxalyl chloride, thionyl chloride, sulfonyl chlorides (functional-group activation & installation)
You want to introduce F (C–F) at a key position (“single-site fluorination”), or perform electrophilic fluorination / deoxyfluorination (OH → F) on an existing scaffold	Table 4	Fluorine chemistry toolbox	Electrophilic fluorinating agents (NFSI, Selectfluor-type); deoxyfluorination (DAST, Deoxo-Fluor-type)
You need to introduce –CF₃ (strongly changing lipophilicity and electronic effects), or do trifluoromethylation transformations	**Table 4	Fluorine chemistry toolbox	TMSCF₃ (Ruppert–Prakash reagent)
Radiochemistry / tracing: you need to improve the usability of [¹⁸F]F⁻ in organic systems for ¹⁸F radiofluorination	Table 4	Fluorine chemistry toolbox	K222 (Kryptofix 2.2.2)
You need an F⁻ source for desilylation / triggering TMSCF₃, etc.: first solve “how to deliver fluoride to the reaction system”	Table 4	Fluorine chemistry toolbox	KF / CsF / TBAF (F⁻ sources; TBAF provided as an aqueous solution)

"Quick selection" mnemonic

• Table 1: isotopes (D) / 3D building blocks (Fsp³) / boron building blocks & boron drugs (B)
• Table 2: practical tools for introducing methyl/methoxy + model controls
• Table 3: halogen “handles” + activation/derivatization via acyl chlorides & sulfonyl reagents
• Table 4: full chain for introducing F / CF₃ / ¹⁸F (fluoride source → fluorination → OH→F → CF₃ → radiolabeling)

Table 1 | Special Elements & Molecular Building Blocks (Stable Isotopes/Deuteration + Fsp³ Building Blocks + Boron Building Blocks & Boron Drugs)

Category	CAS No.	Aladdin Cat. No.	Name	Spec / purity	Product features or applications
Deuterated solvent (NMR)	2206-27-1	D432339	Dimethyl sulfoxide-d₆	Anhydrous grade, ≥99.9 atom% D	One of the most commonly used deuterated NMR solvents; strong solvating power for polar/high-boiling samples—suitable for many polar organics, salts, or poorly soluble samples for spectrum acquisition.
Deuterated solvent (NMR)	865-49-6	C122876	Chloroform-d	100%, 99.96 atom% D	Common deuterated NMR solvent; suitable for most neutral, hydrophobic, or moderately polar organic compounds.
Deuterium source / deuterated solvent (aqueous)	7789-20-0	D113904	Deuterium oxide	≥99.9 atom% D	D₂O: standard solvent for aqueous NMR; also used for H/D exchange, preparing/diluting deuterated systems, and isotope-method controls.
Isotope labeling reagent (deuterated methylation)	865-50-9	I434288	Iodomethane-d₃	≥99.5 atom% D, ≥99%, with copper stabilizer	Deuterated methylation reagent (introduces –CD₃); used to prepare deuterated internal standards and isotope-labeled compounds for metabolism/mechanism studies (strong alkylating agent—strict PPE and controls required).
Hydrophobic rigid Fsp³ fragment (cage hydrocarbon block)	281-23-2	A105219	Adamantane	≥99%	Rigid, cage-like hydrophobic core; often used as a parent building block or reference standard for adamantyl/adamantylamine motifs to increase hydrophobic volume, improve conformational rigidity, and tune permeability-related properties.
Oxetane parent/monomer (Fsp³ small-ring ether)	503-30-0	T162173	Trimethylene oxide	≥98% (GC)	Oxetane parent; can serve as a monomer/starting material for small-ring ether chemistry and polymerization, and for preparing substituted oxetane derivatives.
Oxetane precursor (3-position functionalization entry)	6704-31-0	O129097	3-Oxooxetane	≥95%	3-Oxetanone: a key building block for constructing 3-substituted oxetanes (facilitates installing amines, alcohols, alkyl chains, etc.), enabling diversification of small-ring ether motifs.
Boronic acid building block (Suzuki coupling substrate)	98-80-6	P396095	Phenylboronic acid (PBA) (contains variable amounts of anhydride)	≥99.5%	Classic aryl boronic acid; used in Suzuki–Miyaura coupling to build biaryl/aryl-heteroaryl frameworks; also forms reversible boronate esters with diols (common in analysis/materials contexts).
Borylation reagent (Miyaura borylation / general coupling use)	73183-34-3	B396365	Bis(pinacolato)diboron	≥99%	B₂pin₂: widely used borylation reagent; converts halides/pseudohalides to Bpin intermediates (Miyaura borylation), then used in Suzuki coupling to expand compound libraries.
Approved boron drug (antifungal)	174671-46-6	A125782	5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole	≥98%	Tavaborole (AN-2690)-type boron antifungal; used for antifungal mechanism studies and positive controls; the benzoxaborole pharmacophore enables a distinctive binding mode.
Boron pharmacology tool (PDE4 inhibitor)	906673-24-3	A127102	AN-2728, PDE4 and cytokine release inhibitor	Moligand™, ≥98%	Crisaborole (AN-2728): boron-containing small-molecule PDE4 inhibitor; used as a tool compound/control in inflammation pathway research and PDE4 enzyme/cell assays.
Neuropharmacology tool (NMDA receptor antagonist)	179324-69-7	B125789	TCN 213, reversible proteasome inhibitor	Moligand™, ≥98%	TCN 213 is commonly used as a GluN2A-selective NMDA receptor antagonist/modulator;
Approved boron drug / tool compound (proteasome inhibitor)	1072833-77-2	M128010	Ixazomib (MLN2238)	Moligand™, ≥98%	Ixazomib (MLN2238): reversible proteasome inhibitor (boronic acid pharmacophore); used for proteostasis/ubiquitin–proteasome pathway research and as a positive control.
Approved boron drug / tool compound (β-lactamase inhibitor)	1360457-46-0	V647631	Vaborbactam (RPX7009)	Moligand™, ≥98%	Vaborbactam (RPX7009): cyclic boronic acid pharmacophore β-lactamase inhibitor; used in resistance-mechanism studies, β-lactamase inhibition assays, and antibiotic combination studies as a reference/control.

Table 2 | Methyl / Methoxy Related

Category	CAS No.	Aladdin Cat. No.	Name	Spec / purity	Product features or applications
Methoxy aryl building block / model substrate (aryl ether)	100-66-3	A103684	Anisole	Anhydrous grade, ≥99.7%	Typical aromatic ether containing –OCH₃; used as a solvent/substrate in synthesis and as a starting material/control for aromatic ether derivatives, useful for assessing trends of methoxy introduction on lipophilicity and metabolic sites.
Methoxy + phenolic OH building block / model substrate (aryl phenolic ether)	90-05-1	G112735	Guaiacol	≥98%	Aromatic substrate containing both –OCH₃ and –OH; used as a starting material for fragrance/drug intermediates and for structure controls (to compare “phenolic OH vs methoxy” in polarity, salt formation/binding, and metabolism).
Methylation / carbonate formation reagent (milder; also a solvent)	616-38-6	D119695	Dimethyl carbonate (DMC)	Anhydrous grade, ≥99%	Common methylation/carbonylation reagent and solvent; generally milder than traditional strong methylating agents—used for O-methylation, N-methylation, or carbonate protecting group installation (conditions must be selected per system).
Methylation reagent (sulfonate ester)	80-48-8	M105176	Methyl p-toluenesulfonate	Chemical pure (CP), ≥96%	Electrophilic methylating reagent (sulfonate ester); used for O/N/S methylation and quaternization; relatively strong methyl donor (irritant/hazard—ensure compliance and PPE).
Methylation reagent (sulfonate ester; strong alkylation, research use)	66-27-3	M301750	Methyl methanesulfonate	≥98%	Strong alkylating/methylating agent; used for O/N methylation and quaternization (high toxicity and mutagenicity risk—strict EHS and compliance required).
Methylation reagent (sulfate ester; strong alkylation)	77-78-1	D465758	Dimethyl sulfate	≥98%	Common strong methylating agent in industry and labs; used for O/N methylation and quaternization (high-hazard chemical—ensure compliance and PPE).
Super-strong methylating reagent (“hard methylation”)	333-27-7	M100679	Methyl trifluoromethanesulfonate	≥97%	Extremely strong electrophilic methylating agent (MeOTf); used for difficult methylations/quaternizations/activation (highly moisture-sensitive and reactive—strictly anhydrous handling and protection required).
Methylation reagent (haloalkane, solution form)	74-88-4	I466403	Iodomethane solution	≥99%, 2.0 M in tert-butyl methyl ether	Classic methylating agent; used for O/N/S methylation and methylation of some carbanion systems; solution form facilitates dosing/handling (strong alkylating/toxic—ensure compliance and PPE).

Table 3 | Halogenation / Chlorination & Activation Toolbox

Category	CAS No.	Aladdin Cat. No.	Name	Spec / purity	Product features or applications
Selective chlorinating reagent (mild chlorine source; often for allylic/benzylic)	128-09-6	N431696	N-Chlorosuccinimide	Reagent grade	Common selective chlorinating reagent (solid, relatively convenient handling); used to introduce C–Cl or generate chlorinated intermediates as “reactive handles” for subsequent coupling/substitution (a frequent expansion point in medicinal chemistry synthesis).
Selective brominating reagent (classic for radical bromination)	128-08-5	B105059	N-Bromosuccinimide (NBS)	Chemical pure (CP), ≥98% (T)	Classic bromination reagent; commonly used for allylic/benzylic bromination and constructing brominated intermediates, installing C–Br for downstream substitution/coupling (very common “handle” for analog expansion).
Selective iodinating reagent (high-reactivity iodine source)	516-12-1	I107018	N-Iodosuccinimide	≥97%	Common iodination reagent; generates iodo intermediates (C–I often more reactive) to facilitate downstream coupling or nucleophilic substitution; useful when a more “activated handle” is desired.
Acid chloride formation reagent (activates carboxylic acids to acyl chlorides)	79-37-8	O434200	Oxalyl chloride	Reagent grade, high purity, ≥99%	Common carboxylic-acid activation reagent: converts acids to acid chlorides for making amides, esters, anhydrides, etc.; widely used for “functional-group interconversion and rapid derivatization” of intermediates and drug-like molecules.
General chlorinating/activation reagent (carboxylic acids/alcohols)	7719-09-7	T433841	Thionyl chloride	High purity, reagent grade, ≥99.5%, low iron	General chlorination/activation reagent: often used for carboxylic acid → acid chloride, and for some alcohol → chloride conversions; helps build key intermediates for further derivatization (amide/ester formation, substitution).
Chlorinating agent / chlorine source (sulfuryl chloride)	7791-25-5	S278706	Sulfonyl chloride	AR	Highly reactive functionalization reagent class: used to introduce chlorination, for radical chlorination, or as a chlorine source in certain chlorination systems.

Table 4 | Fluorine Chemistry Toolbox

Category	CAS No.	Aladdin Cat. No.	Name	Spec / purity	Product features or applications
Inorganic fluoride salt (nucleophilic F⁻ source)	7789-23-3	P434124	Potassium fluoride	Suitable for analysis, ACS, premium grade	Common inorganic F⁻ source; used for nucleophilic fluorination/halogen exchange (depending on substrate/conditions), desilylation/activation of silyl intermediates, etc.; used during synthesis to introduce C–F or provide F⁻ (limited solubility—often paired with polar aprotic solvents/phase-transfer systems).
Inorganic fluoride salt (higher activity / often higher effective solubility)	13400-13-0	C755570	Cesium fluoride	UltraBio™, ≥99% (F)	A commonly used “more reactive” inorganic fluoride source; often used for desilylation (TMS/TBS protecting groups), promoting/triggering certain nucleophilic processes, or as an additive in fluorinated-group introduction (in some systems, more effective than KF).
Quaternary ammonium fluoride (soluble/phase-transfer-type F⁻ source; aqueous)	429-41-4	T106822	Tetrabutylammonium fluoride	75% aqueous solution	Common quaternary-ammonium F⁻ source; provided as an aqueous solution suitable for aqueous/mixed-solvent conditions—used for desilylation (deprotection) and generating/releasing nucleophilic F⁻ for subsequent transformations (may be incompatible with strictly anhydrous systems).
Electrophilic fluorinating reagent (NFSI type; mild, selective)	133745-75-2	F122293	N-Fluorobenzenesulfonimide	≥97%	Stable solid electrophilic fluorinating reagent; often used for selective F installation at enolizable/electron-rich sites (e.g., α-fluorination), suitable for “single-site fluorination” to fine-tune physicochemical and metabolic properties.
Electrophilic fluorinating reagent (Selectfluor type; stronger, broad scope)	140681-55-6	S101457	N-Fluoro-N′-(chloromethyl)triethylenediamine bis(tetrafluoroborate)	≥95%	Selectfluor®-type strong electrophilic fluorinating agent; used for electrophilic fluorination and oxidative-fluorination-related transformations across many substrates—useful for rapidly generating fluorinated analog sets for property/activity comparisons in lead optimization.
Deoxyfluorination reagent (alcohol → alkyl fluoride, etc.)	38078-09-0	D111067	Diethylaminosulfur trifluoride (DAST)	≥95%	Classic deoxyfluorination reagent; commonly converts alcohols/–OH to C–F (alkyl fluorides), and can support certain carbonyl-related fluorinations; enables “one-step swap to F” to probe fluorine effects on conformation, polarity, and metabolic stability (sensitive chemistry—strict safety and condition control required).
Deoxyfluorination reagent (DAST alternative / similar; often better substrate tolerance)	202289-38-1	B137512	Bis(2-methoxyethyl)aminosulfur trifluoride	≥90% (T)	Deoxo-Fluor-type reagent; similar use to DAST (often alcohol → alkyl fluoride deoxyfluorination), sometimes offering improved compatibility/handling; used to replace key positions with F for property/metabolism matched-pair studies.
–CF₃ introduction reagent (TMSCF₃; nucleophilic trifluoromethylation)	81290-20-2	T299032	(Trifluoromethyl)trimethylsilane (TFMTMS)	≥98%	Ruppert–Prakash reagent (TMSCF₃); upon F⁻ activation releases an equivalent of “CF₃⁻”, often used for trifluoromethylation of carbonyls and related substrates; a common toolbox reagent for upgrading drug-like molecules with –CF₃ to strongly tune lipophilicity and electronics.
Radiofluorination additive (K⁺ complexation/phase transfer; common for ¹⁸F labeling)	23978-09-8	H119933	4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane	≥98%	Kryptofix 2.2.2 (K222) complexing agent; commonly paired with K⁺/carbonate systems in radiochemistry to increase the availability/reactivity of [¹⁸F]F⁻ in organic media, enabling ¹⁸F radiofluorination (a frequently used additive in PET tracer synthesis).

Note: The above are representative Aladdin products. For additional specifications, please refer to the full product list at the end of the article, or search the Aladdin website by product name/CAS.

Aladdin: https://www.aladdinsci.com/